JSON
Ramos L, Henriksson M, Helleday T, Green AC
Cancer Res. 84 (1) 9-16 [2024-01-02; online 2023-11-03]
The one-carbon folate enzyme methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (MTHFD2) is a promising therapeutic target in cancer. MTHFD2 is upregulated across numerous cancer types, promotes growth and metastasis of cancer, and correlates with poorer survival. Recent studies have developed small-molecule inhibitors to the isozymes MTHFD2 and MTHFD1 that show promise as anticancer agents through different mechanisms. This review discusses the current understanding of the function of MTHFD2 in cancer and the status of inhibitors for treating MTHFD2-overexpressing cancers.
PubMed 37922465
DOI 10.1158/0008-5472.CAN-23-1290
Crossref 10.1158/0008-5472.CAN-23-1290
pii: 730011